Positive Opinion from CHMP for EYLUXVI®
Alteogen Inc. recently celebrated a significant milestone with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) granting a favorable opinion for EYLUXVI® (code name: ALT-L9). This opinion validates the safety and efficacy of EYLUXVI®, a biosimilar referencing the widely used Eylea® (aflibercept).
EYLUXVI®: A Promising Treatment Alternative
Once approved, EYLUXVI® will serve as Alteogen's second biosimilar product, following an anti-cancer Herceptin® biosimilar developed through a strategic partnership with Qilu Pharmaceutical. This new product aims to provide accessibility to essential treatments for patients confronting severe ocular diseases, confirming Alteogen's commitment to innovation and patient care.
Scientific Validation of EYLUXVI®
The positive CHMP opinion hinges on a robust body of evidence, showcasing a substantial analytical, non-clinical, and clinical data package. A pivotal Phase 3 study was conducted, where EYLUXVI® demonstrated comparable efficacy and safety profiles to reference aflibercept among patients suffering from wet age-related macular degeneration (AMD).
Clinical Study Insights
This multi-center, randomized, double-masked Phase 3 study, covering 79 centers across various countries, involved 431 participants. The primary focus was on changes in best corrected visual acuity (BCVA), indicating that EYLUXVI® is potentially equivalent to its reference counterpart in terms of effectiveness.
About Alteogen
Founded in 2008, Alteogen Inc. is a biopharmaceutical firm based in South Korea. The company specializes in the research, development, and commercialization of cutting-edge biologics. Its extensive portfolio encompasses various innovative therapy modalities, including Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars, all developed using proprietary technologies like NexP™-fusion and NexMab™.
Innovative Drug Delivery Systems
One of the standout technologies from Alteogen is its recombinant human hyaluronidase enzyme, created using Hybrozyme™ technology. This advancement allows for the large-scale subcutaneous administration of drugs that traditionally require intravenous infusion, greatly improving patient experience and treatment outcomes.
Future Prospects for Alteogen
Alteogen's achievements extend beyond EYLUXVI®. The company has successfully licensed its ALT-L2 Herceptin® biosimilar to Qilu Pharmaceutical for commercialization in China. Following its recent approval, Qilu is actively bringing this product to market, marking significant progress in Alteogen’s commercial outreach and strategic licensing efforts.
Commitment to Patient Accessibility
The ongoing developments in Alteogen’s pipeline, including EYLUXVI®, reflect the company's dedication to providing treatments that meet patient needs and improving the quality of life for individuals grappling with ocular conditions. With the anticipated approval, Alteogen aims to deliver a vital alternative to standard therapies.
Frequently Asked Questions
What is EYLUXVI®?
EYLUXVI® is a biosimilar product developed by Alteogen, referencing Eylea® (aflibercept), intended for treating various ocular diseases.
Why is the positive CHMP opinion significant?
The positive CHMP opinion signifies that EYLUXVI® has met the necessary standards for efficacy, safety, and quality, which is crucial for market approval in the EU.
What diseases does EYLUXVI® target?
EYLUXVI® targets wet age-related macular degeneration, diabetic macular edema, and visual impairment caused by retinal vein occlusion, among others.
How does Alteogen ensure the quality of its products?
Alteogen emphasizes rigorous analytical, clinical, and non-clinical evaluations to validate the safety and efficacy of its biosimilars.
What is Alteogen's vision for the future?
Alteogen aims to advance biopharmaceutical innovations and expand access to high-quality treatment options for patients worldwide, ensuring a focus on unmet medical needs.
